We took an effective chemotherapy drug and made it much safer, with no side effects.

Conventional chemotherapy damages normal cells as well as cancer cells, causing toxicities that limit treatment. ONX-1006 incorporates proven paclitaxel (PTX) into stable polymeric nanoparticles designed to concentrate PTX in tumors while protecting normal cells.

1. Outstanding Safety Results

• More than 30 preclinical tests and about 4,000 pages of supporting data.
• Excellent safety findings in repeat-dose GLP toxicity studies involving rats and beagle dogs.
• Beagle dogs, once weekly for 4 weeks: No Side Effects at a dose equivalent to about 480 mg PTX for a 60 kg adult.
• Female beagle dogs, once weekly for 13 weeks: No Side Effects at a dose equivalent to about 320 mg PTX for a 60 kg adult.
• Equivalent to 2.4 and 1.6 times a typical 200 mg Abraxane (PTX) dose, respectively. Severe side effects from Abraxane may require dose reductions or treatment discontinuation.

2. Superior Antitumor Efficacy

• 20% greater tumor reduction than Abraxane at the same weekly PTX dose in a pancreatic cancer xenograft study.
• Highest tumor cell death in the comparative study.
• Uses established paclitaxel anticancer activity rather than a new cytotoxic mechanism.

3. Development Goals

• One year or longer of continuous treatment without side effects.
• 90–100% tumor elimination.
• 70% one-year survival rate.

These are future clinical development goals extrapolated from preclinical findings, not demonstrated human clinical outcomes.

4. Pancreatic Cancer Market Opportunity

RASONQUE (Daraxonrasib) – Revolution Medicines (RVMD)

• FDA Approval: Stage IV pancreatic cancer, August 2026.
• One Drug, $45 Billion: Market cap, October 2026.
• Survival Benefit: ~6.5 months longer vs. chemotherapy.
• One-Year Survival Rate: 53.2%.
• Severe Side Effects: 43.6% (Grade ≥3).

Despite advances in pancreatic cancer treatment, severe toxicities and limited long-term survival remain major challenges. We believe ONX-1006 can address both challenges.

5. Manufacturing and Platform Expansion

• Standardized ONX-1006 manufacturing SOP.
• 15 kg of nanoparticles successfully produced.
• Platform expansion across solid tumors and neurological diseases.

6. Our Goals

• Advance ONX-1006 into human clinical evaluation.
• Develop safer, more effective cancer therapies.
• Preserve patients’ quality of life and normal daily living.
• Ultimately help extend and save millions of lives.

We invite investors and strategic partners to join Onselex in transforming cancer treatment and bringing a new generation of therapies to patients worldwide.

For investment or partnership opportunities, please visit our Investment & Partner Inquiry page and complete the inquiry form.

We look forward to welcoming you as part of Onselex’s journey.
Ernest Shin